In rodent animal models, GLP-1RAs increased thyroid paracellular cell (C-cell) proliferation and the incidence of tumors
GLP-1 therapy should not replace established antihypertensive medications and must be prescribed according to NICE guidance for licensed indications

URLs: Tickets: Brochure: Prices: Drug Developer Pricing* - Conference + 2 Workshops : USD 4197.00, Drug Developer Pricing* - Conference + 1 Workshop: USD 3598.00, Drug Developer Pricing* - Conference Only: USD 2999.00, Academic Pricing** - Conference + 2 Workshops: USD 3597.00, Academic Pricing** - Conference + 1 Workshop Only: USD 3098.00, Academic Pricing** - Conference Only: USD 2599.00, Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00, Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00, Solution Provider Pricing - Conference Only: USD 3699.00 Speakers: Adam Bell, Vice President, Translational Medicine and Regulatory Affairs, Neuraly, Andrew Young, Chief Scientific and Medical Officer, I2O Therapeutics, Belle van Rosmalen, Director - Incretin Outcomes, Eli Lilly and Co., Damian Bialonczyk, Global Medical Lead - Metabolism, Roche, David Glass, Vice President - Research, Regeneron, Elisa Araldi, Professor, University of Parma, Hong Chen, Director - Search and Evaluation, Novo Nordisk, Jason Mastaitis, Sr
:max_bytes(150000):strip_icc()/VWHealth-what-kind-of-doctors-you-should-see-if-youre-on-GLP-1-2-f706d7ea26584b0d919320e98e9b9ff8.jpg)
Weight loss medications and treatment plans should never be approached casually, especially when long-term health is the goal
Our team addresses hormonal concerns affecting sleep, mood, weight, and daily life through proven treatment options